Briggs, K. J., Cottrell, K. M., Tonini, M. R., Tsai, A., Zhang, M., Whittington, D. A., . . . Maxwell, J. P. TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor developed for the treatment of MTAP-deleted cancers. Elsevier.
Chicago Style (17th ed.) CitationBriggs, Kimberly J., et al. TNG908 Is a Brain-penetrant, MTA-cooperative PRMT5 Inhibitor Developed for the Treatment of MTAP-deleted Cancers. Elsevier.
MLA (9th ed.) CitationBriggs, Kimberly J., et al. TNG908 Is a Brain-penetrant, MTA-cooperative PRMT5 Inhibitor Developed for the Treatment of MTAP-deleted Cancers. Elsevier.
Warning: These citations may not always be 100% accurate.